BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
BioMarin (BMRN) reported positive Phase 3 results for VOXZOGO in treating hypochondroplasia, showing significant improvements in growth metrics. The company submitted an sNDA to the FDA for this new indication, aiming for a 2027 launch. VOXZOGO is currently approved for achondroplasia.
How this was made
The 30-second read
Why it matters
The trial meets its primary endpoint with significant growth improvements, supporting the sNDA submission.
Market read
First disclosure of pivotal trial data for a new indication, likely to affect BioMarin's valuation and the rare‑disease biotech space.
What to watch
Potential competition from gene‑editing approaches could temper long‑term market share.
Background
BioMarin's VOXZOGO is already approved for achondroplasia; the new data target hypochondroplasia, a rare skeletal disorder with no approved therapy.
Ticker impact
BioMarin announced positive Phase 3 results for VOXZOGO in hypochondroplasia, a new indication not previously approved.
potential upside as investors price in a new label expansion.
Phase 3 data are first-time disclosure, statistically significant, and accompanied by an sNDA filing.
Market effects
strengthens the rare disease/biotech sector and may lift peers with similar FGFR3 targets.
U.S. biotech market could see modest gains; European markets may react to EMA filing.
global interest as the drug is already approved for achondroplasia in multiple regions.
Counterpoint
Regulatory hurdles remain; FDA may demand longer-term data, limiting upside.
Key entities
- CompanyBioMarin Pharmaceutical Inc.
Developer of VOXZOGO, listed on Nasdaq.
- DrugVOXZOGO (vosoritide)
CNP analog currently approved for achondroplasia.
